BOXIT
Disease site: Urological
Treatment Modality: Chemotherapy
Status: Open to recruitment
This trial is a randomised phase III multi-centre double-blind placebo-controlled clinical trial. The primary objective is to determine if the addition of the oral COX-2 inhibitor celecoxib to standard therapy is more effective in terms of disease recurrence at 3 years compared to standard therapy alone for the treatment of superficial TCC of the bladder in intermediate and high risk patients.
BOXIT will randomise 900 patients in the UK.
Associated sub-studies include a Quality of Life study and a Translational (biological sample collection) study.
BOXIT is co-ordinated by the ICR-clinical trials & statistics unit and is supported by the NCRI Bladder Clinical Studies Group.
Chief Investigator: | Mr. John Kelly, University College London |
Sponsor: | Institute of Cancer Research and Cambridge Hospitals NHS Foundation Trust |
Source of funding: | Cancer Research UK, with additional funding in the form of educational grants provided by Kyowa Hakko UK Limited and Cambridge Laboratories Limited. |
ISRCTN: | 84681538 |
In the Clinical Trials Section
